CoChat

Efficiency and Safety of Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody on Hypercholesterolemia: A Meta‐Analysis of 20 Randomized Controlled Trials

Open access
Li, Chuanwei, Lin, Ling, Zhang, Wen, Zhou, Liang, Wang, Hongyong, Luo, Xiaoli, Luo, Hao, Cai, Yue, Zeng, Chunyu · 2015 · Journal of the American Heart Association
Cited by 77

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Background: Proprotein convertase subtilisin/kexin9 ( PCSK 9) monoclonal antibody significantly reduces low‐density lipoprotein cholesterol level in patients with hypercholesterolemia. The goal of this study was to review recently reported randomized controlled trials to investigate the therapeutic effects and safety of PCSK 9 inhibitors. Methods and Results: The clinical randomized controlled trials published from inception to March 19, 2015 were identified from The Cochrane Library databases, PUBMED , and EBASE . Randomized controlled trials of at least 8 weeks duration using PCSK 9 inhibitors in treating patients with hypercholesterolemia were included. Mean difference ( MD ) with a 95% CI was used to calculate the continuous data, the standardized mean difference with a 95% CI was used when the unit was not unified, and risk ratio with a 95% CI was used for dichotomous data. After screening, 20 trials fulfilled the inclusion criteria. PCSK 9 inhibitors significantly decreased the levels of low‐density lipoprotein cholesterol ( MD =−65.29 mg/dL, 95% CI : −72.08 to −58.49), total cholesterol ( MD =−60.04 mg/dL, 95% CI : −69.95 to −50.13), triglycerides ( MD =−12.21 mg/dL, 95% CI : −16.21 to −8.22) and apolipoprotein‐B ( MD =−41.01 mg/dL, 95% CI : −46.07 to −35.94), lipoprotein(a) (standardized mean difference=−0.94, 95% CI : −1.12 to −0.77) and increased the levels of high‐density lipoprotein cholesterol ( MD =3.40 mg/dL, 95% CI : 3.12 to 3.68) and apolipoprotein‐A1 ( MD =6.75 mg/dL, 95% CI : 4.64 to 8.86). There was no significant difference in the incidence of treatment‐emergent adverse events (risk ratio=1.01, 95% CI : 0.98 to 1.04), serious treatment‐emergent adverse events (risk ratio=1.01, 95% CI : 0.88 to 1.17), and the discontinuation of treatment between the 2 groups (risk ratio=1.07, 95% CI : 0.86 to 1.34). Conclusions: The meta‐analysis indicated that PCSK 9 inhibitors had a strong effect in lowering low‐density lipoprotein cholesterol and other lipid levels with satisfactory safety and tolerability in patients with hypercholesterolemia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/jaha.115.001937

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 77

Metadata

Authors
Li, C., Lin, L., Zhang, W., Zhou, L., Wang, H., Luo, X., Luo, H., Cai, Y., & Zeng, C.
Venue
Journal of the American Heart Association
Published
2015-06-15
Volume
4
Issue
6
Pages
e001937-e001937
ISSN
2047-9980 (ISSN-L)
OpenAlex
W2157838461
Cited by
77
References
16
FWCI
15.76
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficiency and Safety of Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody on Hypercholesterolemia: A Meta‐Analysis of 20 Randomized Controlled Trials. https://app.cochat.ai/papers/10.1161/jaha.115.001937
The paper
Li, C., Lin, L., Zhang, W., Zhou, L., Wang, H., Luo, X., Luo, H., Cai, Y., & Zeng, C. (2015). Efficiency and Safety of Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody on Hypercholesterolemia: A Meta‐Analysis of 20 Randomized Controlled Trials. Journal of the American Heart Association. https://doi.org/10.1161/jaha.115.001937

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.